Vanda Pharmaceuticals (NASDAQ:VNDA) Raised to “Strong-Buy” at Zacks Research

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. UBS Group reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. HC Wainwright raised their price objective on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group increased their target price on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research report on Wednesday, December 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.63.

Vanda Pharmaceuticals Trading Down 17.6%

NASDAQ VNDA opened at $6.12 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 3.10. The firm’s 50-day moving average is $7.34 and its two-hundred day moving average is $5.67. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60. The stock has a market capitalization of $361.69 million, a P/E ratio of -1.64 and a beta of 0.62.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The firm had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 21.88%. On average, sell-side analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Empire Financial Management Company LLC grew its position in Vanda Pharmaceuticals by 46.2% during the 4th quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock worth $9,775,000 after purchasing an additional 350,154 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Vanda Pharmaceuticals by 73.8% during the fourth quarter. Alps Advisors Inc. now owns 48,522 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 20,597 shares during the last quarter. Nuveen LLC increased its position in Vanda Pharmaceuticals by 70.4% in the 4th quarter. Nuveen LLC now owns 291,473 shares of the biopharmaceutical company’s stock valued at $2,571,000 after acquiring an additional 120,428 shares during the period. Janney Montgomery Scott LLC acquired a new position in Vanda Pharmaceuticals in the 4th quarter valued at about $1,548,000. Finally, JPMorgan Chase & Co. raised its stake in Vanda Pharmaceuticals by 98.1% during the 4th quarter. JPMorgan Chase & Co. now owns 396,017 shares of the biopharmaceutical company’s stock valued at $3,493,000 after acquiring an additional 196,124 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Key Headlines Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Fanapt momentum: Full‑year 2025 Fanapt net sales rose 24% to $117.3M, driven by higher prescriptions — supports durable product revenue growth. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: NEREUS approval and Bysanti PDUFA: NEREUS (tradipitant) approved for prevention of motion‑induced vomiting; Bysanti (milsaperidone) NDA under FDA review with PDUFA target Feb 21, 2026 — a potential upside catalyst if approved. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage mixed but constructive: recent buy/overweight ratings and price targets remain above the current share price (median target ~$12.50), indicating upside in some broker forecasts. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Earnings miss and widening net loss: Q4 revenue (~$56–57M) missed estimates and diluted EPS was -2.39, substantially below forecasts; the company reported a large net loss and gross loss for the quarter. Vanda Pharmaceuticals Inc (VNDA) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Below‑consensus FY2026 revenue guidance: company guided to $230M–$260M vs. consensus ~$273M — guidance shortfall weighs on near‑term expectations. (Guidance noted in company release and market reports.)
• Negative Sentiment: Cash burn and balance sheet pressure: operating cash outflow increased, cash and equivalents fell to roughly $70M, and liabilities rose — increases focus on runway and financing risk. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Investor litigation announced: Pomerantz LLP is investigating claims on behalf of Vanda investors — adds legal risk and near‑term uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.